Patient Preferences for Chronic Myeloid Leukemia Medication Regimen Attributes and their Potential Impact on Adherence: Results from a Multi-national Conjoint Study
Author:
Affiliation:
1. Bristol-Myers Squibb, Wallingford, CT, USA
2. ICON PRO, Bethesda, Maryland, USA
3. University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
4. Bristol-Myers Squibb, Princeton, NJ, USA
Abstract
Publisher
The Journal of Health Economics and Outcomes Research
Subject
General Earth and Planetary Sciences
Link
https://jheor.org/article/9890.pdf
Reference18 articles.
1. Jemal A, Siegel R, Ward E, et al:Cancer statistics, 2007.CA Cancer J Clin 2008;58:71-96.
2. Huang X, Cortes J, Kantarjian H: Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.Cancer 2012;118:3123-7.
3. Noens L, van Lierde M-A, De Bock R, et al: Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study.Blood2009;113:5401-11.
4. Marin D, Bazeos A, Mahon F-X, et al: Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010;28:2381-8.
5. Kelley RK, Venook AP: Nonadherence to imatinib during an economic downturn.N Engl J Med 2010;363:596-98.
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3